| Paul S. Aisen | |
|---|---|
| Photo placeholder | |
| Affiliations | University of Southern California |
| Country | USA |
| H-index | 180 |
| ORCID | 0000-0002-3696-418X |
| Research Focus | Alzheimer's Disease |
| Mechanisms | Clinical trials, Immunotherapy, Amyloid |
Paul S. Aisen is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Paul S. Aisen is a renowned neurologist and neuroscientist specializing in Alzheimer's disease research and clinical trials. As a professor at the University of Southern California (USC) and founding director of the Alzheimer's Disease Cooperative Study (ADCS)[1], Aisen has been instrumental in advancing therapeutic strategies for Alzheimer's disease over the past three decades.
With an h-index of 180, Aisen is among the most cited researchers in the neuroscience field, having authored over 600 peer-reviewed publications. His leadership in designing and conducting Alzheimer's clinical trials has shaped the field's understanding of disease modification[2].
Aisen pioneered novel clinical trial designs for Alzheimer's disease, including:
His work on amyloid-targeting immunotherapies has been foundational:
Aisen has advanced the use of biomarkers in clinical trials:
Alzheimer's disease clinical trials. Lancet Neurol, 2020.
The role of flutemetamel F18 amyloid imaging in dementia. Neurobiol Aging, 2015.
Alzheimer's disease: are we close to effective treatments?. Lancet, 2016.
Amyloid-related imaging abnormalities in Alzheimer's disease trials. Neurology, 2015.
Cognitive outcomes in trials of antibodies for Alzheimer's disease. JAMA Neurol, 2019.
Recent publications from Aisen's group include advances in:
Dr. Aisen has trained numerous researchers in the field of neurodegenerative diseases. His/her laboratory has hosted postdoctoral fellows, graduate students, and visiting scientists from around the world.
Future research directions include:
Dr. Aisen maintains collaborations with:
The study of Paul S. Aisen has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Alzheimer's Disease Cooperative Study (ADCS). National Institute on Aging. Website
Aisen PS, et al. (2017). "Reimagining Alzheimer's disease clinical trials: A strategic approach." Alzheimer's & Dementia. DOI
Honig LS, et al. (2023). "Lecanemab in early Alzheimer's disease." NEJM. DOI
Sperling RA, et al. (2011). "Toward defining the preclinical stages of Alzheimer's disease." Alzheimer's & Dementia. DOI
Aisen PS. (2011). "The development of anti-amyloid therapy for Alzheimer's disease." CNS Drugs. DOI
Page updated: 2026-03-05